Carboplatin and Kidney Function in Cancer Patients
Author Information
Author(s): M.D. Mason, J. Nicholls, A. Horwich
Primary Institution: Royal Marsden Hospital
Hypothesis
Does carboplatin cause significant renal toxicity in patients with metastatic germ cell tumours?
Conclusion
Carboplatin does not cause significant renal toxicity in patients with metastatic germ cell tumours.
Supporting Evidence
- 44 patients were evaluated for changes in kidney function after treatment with carboplatin.
- No significant differences in kidney function were found after treatment.
- 21% of patients experienced a fall in kidney function of 10% or more, but many had other contributing factors.
Takeaway
Doctors wanted to see if a cancer drug called carboplatin hurts the kidneys. They found out it doesn't really cause kidney problems.
Methodology
Renal function was measured before and after chemotherapy in 62 patients, with 44 evaluable patients analyzed for changes in glomerular filtration rate (GFR).
Limitations
Eighteen patients were excluded due to urinary tract obstruction, which may limit the generalizability of the findings.
Participant Demographics
Mean age of patients was 35.8 years for single agent carboplatin and 28 years for carboplatin plus other agents.
Statistical Information
P-Value
0.58
Statistical Significance
p=0.58
Want to read the original?
Access the complete publication on the publisher's website